THR-β agonists have great potential for the treatment of MASLD, MASH, and related sequelae through their selective effect on the liver by reducing systemic side effects, including thyrotoxicosis. This evidence concerns the gene THRB and metabolic dysfunction-associated steatotic liver disease.